Camp4 Therapeutics Corp

CAMP

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001736730

SEC filings (opens in a new tab)

In the last 90 days, Camp4 Therapeutics Corp insiders filed 1 open-market purchase and 4 sales; 61 institutions reported holding it in 13F filings for Q2 2026, worth $182.2M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026: $238.5M
Insider buysLast 90 days, $39.6K in total: 1
Insider sellsLast 90 days, $2.50M in total: 4
13F holdersQ2 2026, +16 vs. previous quarter: 61
13F valueReported value at the end of Q2 2026: $182.2M
Superinvestors holdingAt the end of Q2 2026: 0

Price chart

Chart by TradingView (opens in a new tab)

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $3.50M; +436.5% year over year
Net income, FY2025: -$80.4M; No comparable prior period
Free cash flow, FY2025: -$29.8M; No comparable prior period
Revenue, Q3 FY2026: $1.90M; +138.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $80.4M (2298.5% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest: 3.26M; Shares sold short
Change: −191.8K; −5.6% vs. previous
Days to cover: 23.66; At average daily volume

Superinvestors holding CAMP, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding CAMP at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Camp4 Therapeutics Corp insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Sep 2, 2026 (view filing)7:50 PM ET	Aug 31	2 days	Gold KellyChief Financial Officer	PPurchase	+10.0K	$3.96	+$39.6K	New position10.0K after
Aug 31, 2026 (view filing)5:05 PM ET	Aug 27	4 days	Schwab Andrew J.Director	SSale	−400.0K	$4.04	−$1.62M	−16.4%2.03M after
Aug 26, 2026 (view filing)4:57 PM ET	Aug 24	2 days	Schwab Andrew J.Director	SSale	−10	$4.50	−$45	0.0%2.43M after
Aug 21, 2026 (view filing)4:59 PM ET	Aug 19-21	2 days	Schwab Andrew J.Director	SSale	−191.9K	$4.59	−$879.7K	−7.3%2.43M after	3 lots
Aug 19, 2026 (view filing)8:46 PM ET	Aug 19	Same day	Tardiff DanielChief Scientific Officer	SSale	−1.74K	$4.76	−$8.27K	−100.0%0 after
Aug 5, 2026 (view filing)5:39 PM ET	Aug 3	2 days	Parmar Kush and 6 others10% Owner	PPurchase	+3.18M	$1.53	+$4.86M	–3.18M after	Derivative
Aug 5, 2026 (view filing)5:09 PM ET	Aug 3	2 days	Young Richard ADirector	PPurchase	+16.4K	$1.65	+$27.0K	+9.6%186.4K after
Aug 5, 2026 (view filing)5:08 PM ET	Aug 3	2 days	Maricich YuriChief Medical Officer	PPurchase	+6.55K	$1.65	+$10.8K	+108.1%12.6K after
Aug 5, 2026 (view filing)5:08 PM ET	Aug 3	2 days	Gold KellyChief Financial Officer	PPurchase	+6.55K	$1.65	+$10.8K	+9.7%74.4K after
Aug 5, 2026 (view filing)5:07 PM ET	Aug 3	2 days	Mandel-Brehm JoshChief Executive Officer	PPurchase	+6.55K	$1.65	+$10.8K	+2.4%285.0K after

Top 10 13F holders, Q2 2026

See all 61 holders

The largest institutional positions in Camp4 Therapeutics Corp at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding CAMP in Q2 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
Jupiter Topco LLC	6,307,636	$27.6M	0.01%	+6,307,636	New
5AM Venture Management, LLC	5,869,091	$25.6M	8.91%	00.0%	Unchanged
FMR LLC	4,904,339	$21.4M	0.00%	−29,093−0.6%	Reduced
Vivo Capital, LLC	4,246,568	$18.6M	1.69%	00.0%	Unchanged
Balyasny Asset Management LLC	2,575,724	$11.3M	0.02%	−56,713−2.2%	Reduced
AH Capital Management, L.L.C.	2,125,339	$9.29M	0.07%	00.0%	Unchanged
Adage Capital Partners GP, L.L.C.	1,960,784	$8.57M	0.01%	00.0%	Unchanged
Trails Edge Capital Partners, LP	1,932,937	$8.45M	1.34%	−6,626−0.3%	Reduced
BlackRock, Inc.	1,644,134	$7.18M	0.00%	+1,187,763+260.3%	Added
Vanguard Capital Management LLC	1,533,489	$6.70M	0.00%	−1,279−0.1%	Reduced

Holders of 5% or more of CAMP

See all 8 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Camp4 Therapeutics Corp.

Largest holders of CAMP from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Janus Henderson Group PLC	13G	12.20%6.31M shares	New	Jan 8, 20261 filing	Jan 8, 2026	SEC
Coastlands Capital LP	13G/A	9.99%4.89M shares	−0.01 ppfrom 10.00%	Sep 16, 20252 filings	Dec 11, 2025	SEC
5AM Ventures VI, L.P.	13D/A	9.90%6.38M shares	0.00 ppfrom 9.90%	Oct 22, 20244 filings	Aug 31, 2026	SEC
FMR LLC	13G/A	7.80%4.91M shares	−1.70 ppfrom 9.50%	Oct 7, 20254 filings	Nov 5, 2026	SEC
Vivo Opportunity Fund Holdings, L.P.	13G/A	7.40%3.86M shares	−0.20 ppfrom 7.60%	Sep 17, 20252 filings	Feb 13, 2026	SEC